Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astellas Pharma Inc (ALPMF)

Astellas Pharma Inc (ALPMF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.6890 +3.57%
on 10/02/19
14.2600 -0.58%
on 10/01/19
+0.7380 (+5.49%)
since 08/22/19
3-Month
13.3500 +6.20%
on 08/15/19
14.6300 -3.09%
on 07/22/19
-0.5420 (-3.68%)
since 07/02/19
52-Week
12.7600 +11.11%
on 12/31/18
16.9100 -16.16%
on 10/16/18
-3.2320 (-18.56%)
since 10/01/18

Most Recent Stories

More News
Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier...

ALPMF : 14.1780 (+0.34%)
Astellas Oncology Announces 2019 C3 Prize® Finalists

Astellas Pharma US, Inc. ("Astellas") today announced the finalists for its fourth annual C3 (Changing Cancer Care) Prize, a challenge that funds the best ideas beyond medicine to improve cancer care for...

ALPMF : 14.1780 (+0.34%)
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

ALPMF : 14.1780 (+0.34%)
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A Schoeneck., "FibroGen") today announced that Japan's Ministry...

ALPMF : 14.1780 (+0.34%)
FGEN : 37.29 (+1.75%)
Mission Bay Capital Announces $60 Million Fund III

Mission Bay Capital, an early-stage life-science venture capital firm investing in innovative entrepreneurs working on vital medical and environmental challenges, announced the closing of its third fund...

ALPMF : 14.1780 (+0.34%)
Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Astellas Venture Management, LLC (President: Shunichiro Matsumoto, Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...

ALPMF : 14.1780 (+0.34%)
Kidney Transplantation Therapeutics Market - Global Forecast and Analysis 2019-2023: Increasing Strategic Alliances & Reimbursement Policies - ResearchAndMarkets.com

The "Kidney Transplantation Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering. The global kidney transplantation...

ALPMF : 14.1780 (+0.34%)
NVS : 86.60 (+0.78%)
LFCYF : 0.5200 (-2.80%)
U.S. FDA Grants XTANDI(R) (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review...

ALPMF : 14.1780 (+0.34%)
PFE : 36.11 (+0.89%)
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced dosing of the first patient in the SKYLIGHT 1(TM) Phase 3 pivotal trial for fezolinetant, an investigational...

ALPMF : 14.1780 (+0.34%)
Sponsors Announced for 2019 Ellie Mae Classic

The Korn Ferry Tour and Ellie Mae Classic, sponsored by Ellie Mae(R) - the leading cloud-based platform provider for the mortgage finance industry - today announced the sponsors for the 2019 Ellie Mae...

ALPMF : 14.1780 (+0.34%)
ELLI : 98.99 (unch)
EFX : 143.93 (+1.71%)
TREE : 312.02 (+1.13%)
Trade ALPMF with:

Key Turning Points

2nd Resistance Point 14.1780
1st Resistance Point 14.1780
Last Price 14.1780
1st Support Level 14.1780
2nd Support Level 14.1780

See More

52-Week High 16.9100
Fibonacci 61.8% 15.3247
Fibonacci 50% 14.8350
Fibonacci 38.2% 14.3453
Last Price 14.1780
52-Week Low 12.7600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar